Send to a Friend Share

JP Morgan Upgrades Ariad Pharmaceuticals (ARIA) to Overweight

November 9, 2009 8:34 AM EST
ARIA Hot Sheet
Rating Summary:
    10 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 7 | New: 23
JP Morgan upgrades Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) Neutral to Overweight with a $6 price target.

ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the United States and Europe.

You May Also Be Interested In


Related Categories

Trader Talk, Upgrades

Related Entities

JPMorgan

Add Your Comment





Follow StreetInsider.com On Twitter